<DOC>
	<DOCNO>NCT00765726</DOCNO>
	<brief_summary>The purpose study collect safety information associate use Xyntha usual care set . Upon meet eligibility criterion , patient require approximately 5 study visit 2 year period . Procedures complete throughout study include collection vital sign , physical exam , laboratory assessment . Patients require complete infusion log Xyntha infusion .</brief_summary>
	<brief_title>Study Evaluating The Safety Of Xyntha In Usual Care Settings</brief_title>
	<detailed_description>The study terminate May 12 , 2011 due poor enrollment prospect study 's similarity another ongoing trial ReFacto AF . The termination study impact subject safety well . The decision terminate trial base safety concern .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male patient 12 year age old . Patients transition Xyntha recombinant plasmaderived FVIII replacement product . Treatment history 150 great exposure day FVIII product prior Enrollment visit . Negative inhibitor screen documentation negative inhibitor titer within 6 week less prior study entry except patient enter study immune tolerance induction therapy . Bleeding disorder hemophilia A. Inhibitor titer great equal 0.6 BU screen except patient immune tolerance induction therapy . Immunomodulatory therapy screen period . Known hypersensitivity hamster protein .</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>hemophilia</keyword>
	<keyword>hemophilia A</keyword>
	<keyword>ReFacto</keyword>
	<keyword>Xyntha</keyword>
	<keyword>moroctocog alfa</keyword>
	<keyword>bleed disorder</keyword>
</DOC>